Biotech archive
Every Biotech story, newest first. 88 in this archive.
Aug 5, 2026
XunZi Writes Hypotheses, Not Headlines: Nature Paper Validates CHK2 in Parkinson's via AI Biologist
Nature Biomedical Engineering publishes XunZi, an AI biologist trained on 24.4 million papers that identifies CHK2 as a Parkinson's target validated in mouse models.
Aug 4, 2026
Design-Make-Test-Learn: Receptor.AI and Sethera Close the Loop on Polymacrocyclic Peptides
Receptor.AI and Sethera Therapeutics announced an August 3 alliance pairing encoded polymacrocyclic peptide libraries with physics-based AI for a design-make-test-learn workflow on hard-to-drug targets.
Aug 3, 2026
Forty Percent Is Not a Phase: SMDD-Bench Stress-Tests Structure-Based Drug Design Where Leaderboards Lie
SMDD-Bench, a new structure-based drug design benchmark on arXiv 2605.21740, reports GPT-5.4 at 40.2%—a sobering external scorecard for generative chemistry in protein pockets.
Aug 2, 2026
Patent the Meaning Layer: MindWalk Locks In HYFT Biology Architecture
MindWalk's July EP26187897.9 filing targets the HYFT representation layer beneath ReefIQ and LensAI — as pharma AI shifts from models to proprietary biological data infrastructure.
Aug 1, 2026
The Verification Era Begins: Insilico Doses First Patients in Phase III Rentosertib Trial
Insilico Medicine doses first patients in a 320-person Phase III trial of rentosertib—marking AI drug discovery's entry into the verification era.
Aug 1, 2026
Petascale Perturbations: GSK Bets $110M on Relation's MORGAN Foundation Model
Relation Therapeutics announced a $110M GSK research pact and unveiled MORGAN, a cellular perturbation foundation model, on July 30, 2026 — betting that petascale human biology data can sharpen AI drug discovery.
Jul 31, 2026
From Reactive to Resilient: Google DeepMind and Isomorphic Labs Chart a Biosecurity Stack
Google DeepMind and Isomorphic Labs outline a bioresilience framework pairing gated model access with rapid countermeasure deployment amid dual-use biology debates.
Jul 31, 2026
Receipts, Not Roadmaps: Chai Discovery's $400M Round Marks AI Drug Design's Commercial Turn
Chai Discovery closed a $400M Series C at a $3.8B valuation with Eli Lilly, Pfizer, and Novartis as paying customers — even though no AI-designed drug has reached FDA approval yet.
Jul 31, 2026
Fast Track for an AI Drug: Insilico's ISM6331 Wins FDA Priority Review Path in Mesothelioma
Insilico Medicine's AI-designed pan-TEAD inhibitor ISM6331 received FDA Fast Track Designation for advanced mesothelioma — the first such designation for a program in the company's generative-AI pipeline.
Jul 31, 2026
Beyond Memorization: Insilico's DDD Benchmark Tests Whether AI Can Actually Discover Drugs
Insilico Medicine launches DDD Benchmark as a Service — decontaminated real-world drug-discovery evaluation for frontier AI models, with 300+ foundation tests and proprietary candidate baselines.
Jul 30, 2026
The Data Moat: Relation's $110M GSK Pact and the MORGAN Cellular Foundation Model
Relation Therapeutics expands GSK partnership to $110M, unveils MORGAN cellular foundation model, and commits to an automated London wet lab generating petascale perturbation data for AI drug discovery.
Jul 30, 2026
The Kinase Atlas: KinoPlex Maps Phosphorylation Across the Human Proteome
KinoPlex maps ~250,000 high-confidence phosphorylation candidates across the human proteome using AlphaFold structures and kinase motifs — published in Nature Biotechnology July 29.
Jul 30, 2026
First Fast Track: Insilico's ISM6331 Marks an AI Pipeline Coming of Age
Insilico Medicine received FDA Fast Track Designation on July 29 for ISM6331, its AI-designed pan-TEAD inhibitor in pretreated unresectable malignant pleural mesothelioma — the first Fast Track in its generative pipeline.
Jul 30, 2026
The Discovery Desk: Ono Pharmaceutical Embeds Phylo's Biomni Lab Across Its Scientists
Ono Pharmaceutical deploys Phylo's Biomni Lab agentic AI platform across its full discovery organization — a platform bet, not an asset-specific deal.
Jul 29, 2026
The Design Engine: IsoDDE Pushes Isomorphic Labs Beyond AlphaFold 3's Structure Ceiling
Isomorphic Labs' IsoDDE claims to double AlphaFold 3 accuracy on hard protein-ligand cases and predict binding affinity rivaling FEP+.
Jul 29, 2026
The Bunsen Reversal: Schrödinger's Physics Agent and the CEO Who Couldn't Stay Skeptical
Schrödinger CEO Ramy Farid launches Bunsen, an LLM-wrapped agent for the company's physics simulations, after years of AI skepticism — early demos cut multi-hour STAT6 analyses to minutes.
Jul 29, 2026
The Closed Loop: Why AI Drug Discovery Needs Negative Data and FAIR Lab Infrastructure
MIT Technology Review and Cytiva's Paul Belcher argue AI drug discovery's next bottleneck is closing the data loop — especially negative results and FAIR lab infrastructure.
Jul 29, 2026
The GTX Bench: A Lightweight Generative Drug-Discovery Assistant Built for 4 GB GPUs
A Scientific Reports study published July 18 packages generative molecule design, Tox21 toxicity screening, and ESMFold structure calls into one pipeline tuned for 4 GB GPUs.
Jul 28, 2026
The Stability Floor: Broad Institute Shows AI Redesign Unlocks Better Protein Evolution Outcomes
Broad Institute researchers show ProteinMPNN-redesigned proteases outperform wild-type starting points in PACE evolution, yielding a 79-fold ataxin-2 specificity gain in Nature.
Jul 28, 2026
The Unified Oracle: PeptiVerse Maps Developability Across Canonical Sequences and Modified Peptide Chemistry
PeptiVerse unifies developability prediction for canonical sequences and modified peptide SMILES, targeting the computational gap between small-molecule ADMET tools and protein-only predictors.